(A) The transcriptional levels of CBX7 were tested in CGGA, TCGA, REMBRANDT, and GSE16011 glioma datasets. (B) Kaplan-Meier survival curve was used to estimate the survival outcomes of patients divided into two groups with CBX7 low/high level. (C) Western blot analysis was used to test the levels of CBX7 in different glioma samples and normal brain tissues. Tubulin was used as a loading control. (D) Q-PCR was performed to determined CBX7 levels among NBT, LGG and HGG samples.